NO993779L - Fremgangsmaate for krystallisering av en revers transkriptaseinhibitor ved anvendelse av et anti-lösningsmiddel - Google Patents

Fremgangsmaate for krystallisering av en revers transkriptaseinhibitor ved anvendelse av et anti-lösningsmiddel

Info

Publication number
NO993779L
NO993779L NO993779A NO993779A NO993779L NO 993779 L NO993779 L NO 993779L NO 993779 A NO993779 A NO 993779A NO 993779 A NO993779 A NO 993779A NO 993779 L NO993779 L NO 993779L
Authority
NO
Norway
Prior art keywords
solvent
crystallization
procedure
reverse transcriptase
transcriptase inhibitor
Prior art date
Application number
NO993779A
Other languages
English (en)
Other versions
NO993779D0 (no
NO320128B1 (no
Inventor
William Clarke
Louis S Crocker
Ii Joseph L Kukura
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451618&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO993779(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9706046.1A external-priority patent/GB9706046D0/en
Priority claimed from GBGB9709348.8A external-priority patent/GB9709348D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO993779D0 publication Critical patent/NO993779D0/no
Publication of NO993779L publication Critical patent/NO993779L/no
Publication of NO320128B1 publication Critical patent/NO320128B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO19993779A 1997-02-05 1999-08-04 Fremgangsmate for krystallisering av en revers transkriptaseinhibitor ved anvendelse av et anti-losningsmiddel NO320128B1 (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3738597P 1997-02-05 1997-02-05
GBGB9706046.1A GB9706046D0 (en) 1997-03-24 1997-03-24 Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
US4280797P 1997-04-08 1997-04-08
GBGB9709348.8A GB9709348D0 (en) 1997-05-07 1997-05-07 Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
PCT/US1998/001999 WO1998033782A1 (en) 1997-02-05 1998-02-02 Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent

Publications (3)

Publication Number Publication Date
NO993779D0 NO993779D0 (no) 1999-08-04
NO993779L true NO993779L (no) 1999-10-05
NO320128B1 NO320128B1 (no) 2005-10-31

Family

ID=27451618

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19993779A NO320128B1 (no) 1997-02-05 1999-08-04 Fremgangsmate for krystallisering av en revers transkriptaseinhibitor ved anvendelse av et anti-losningsmiddel

Country Status (18)

Country Link
EP (1) EP0975609B1 (no)
JP (6) JP3418626B2 (no)
KR (1) KR100573192B1 (no)
CN (2) CN1073991C (no)
AT (1) ATE486065T1 (no)
AU (1) AU738545C (no)
CA (1) CA2279198C (no)
CZ (2) CZ297535B6 (no)
DE (1) DE69841972D1 (no)
EA (1) EA001805B1 (no)
EE (1) EE03827B1 (no)
HU (1) HU229087B1 (no)
IL (1) IL130715A (no)
NO (1) NO320128B1 (no)
NZ (1) NZ336510A (no)
PL (1) PL197740B1 (no)
SK (1) SK284935B6 (no)
WO (1) WO1998033782A1 (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU229087B1 (en) * 1997-02-05 2013-07-29 Merck Sharp & Dohme Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
AR011731A1 (es) * 1997-05-16 2000-08-30 Merck & Co Inc Un proceso de reaccion de adicion enantioselectiva eficiente utilizando un reactivo de organozinc.
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
HRP990182A2 (en) * 1998-06-11 2000-02-29 Du Pont Pharm Co Crystalline efavirenz
GB9828721D0 (en) * 1998-12-24 1999-02-17 Glaxo Group Ltd Novel apparatus and process
WO2006018853A2 (en) 2004-08-19 2006-02-23 Hetero Drugs Limited Novel polymorphs of efavirenz
WO2008108630A1 (en) * 2007-03-02 2008-09-12 Ultimorphix Technologies B.V. Polymorphic forms of efavirenz
US8318930B2 (en) * 2007-12-24 2012-11-27 Matrix Laboratories Limited Process for preparing polymorphic forms of (S)-6-chloro-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
US8383811B2 (en) 2008-12-22 2013-02-26 Hetero Research Foundation Process for preparing efavirenz polymorph
DE102009041443A1 (de) 2009-09-16 2011-03-31 Archimica Gmbh Salze des 6-Chlor-4-(cyclopropylethinyl)-1,4-dihydro-4-(trifluormethyl)-2H-3,1-benzoxazin-2-ons und deren Synthese, Aufreinigung und Anwendung als Vorstufen für Efavirenz
EP2471783A1 (en) 2010-12-23 2012-07-04 Esteve Química, S.A. Novel polymorphic form of efavirenz
CN103508973B (zh) * 2012-06-25 2016-04-27 上海迪赛诺药业有限公司 制备依非韦伦i型结晶的方法
CN105037175B (zh) * 2014-07-18 2017-02-22 盐城迪赛诺制药有限公司 一种用于提高依非韦伦中间体光学纯度的方法
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG10201913990RA (en) 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
CN114195761B (zh) * 2021-12-23 2023-04-14 浙江普洛家园药业有限公司 一种高纯度西他沙星3/2水合物的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1282405C (en) * 1984-05-21 1991-04-02 Michael R. Violante Method for making uniformly sized particles from water-insoluble organic compounds
US5665720A (en) * 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
IL106507A (en) * 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
WO1995020389A1 (en) * 1994-01-28 1995-08-03 Merck & Co., Inc. Benzoxazinones as inhibitors of hiv reverse transcriptase
US5663467A (en) * 1995-01-23 1997-09-02 Merck & Co., Inc. Synthesis of cyclopropylacetylene
US5633405A (en) * 1995-05-25 1997-05-27 Merck & Co., Inc. Asymmetric synthesis of (-)-6-chloro-4-cyclopropyl-ethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxanzin-2-one
HU229087B1 (en) * 1997-02-05 2013-07-29 Merck Sharp & Dohme Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
AU6876898A (en) * 1997-04-07 1998-10-30 Du Pont Pharmaceuticals Company Asymmetric synthesis of benzoxazinones via new intermediates

Also Published As

Publication number Publication date
CA2279198C (en) 2009-04-14
JP2013139484A (ja) 2013-07-18
CN1073991C (zh) 2001-10-31
CN1385425A (zh) 2002-12-18
JP6126172B2 (ja) 2017-05-10
NZ336510A (en) 2001-04-27
JP2015205914A (ja) 2015-11-19
JP3418626B2 (ja) 2003-06-23
CZ304186B6 (cs) 2013-12-11
CA2279198A1 (en) 1998-08-06
IL130715A (en) 2003-07-31
HU229087B1 (en) 2013-07-29
NO993779D0 (no) 1999-08-04
EA001805B1 (ru) 2001-08-27
ATE486065T1 (de) 2010-11-15
EP0975609A1 (en) 2000-02-02
EA199900720A1 (ru) 2000-04-24
WO1998033782A1 (en) 1998-08-06
PL197740B1 (pl) 2008-04-30
CZ297535B6 (cs) 2007-01-03
PL334478A1 (en) 2000-02-28
CN1191242C (zh) 2005-03-02
JP5295190B2 (ja) 2013-09-18
DE69841972D1 (de) 2010-12-09
JP2000507972A (ja) 2000-06-27
NO320128B1 (no) 2005-10-31
EP0975609A4 (en) 2001-02-21
JP2003040874A (ja) 2003-02-13
CZ276599A3 (cs) 2000-02-16
EE03827B1 (et) 2002-08-15
SK284935B6 (sk) 2006-02-02
EE9900341A (et) 2000-02-15
HUP0001313A3 (en) 2002-12-28
HUP0001313A2 (hu) 2000-10-28
AU738545B2 (en) 2001-09-20
KR100573192B1 (ko) 2006-04-24
AU738545C (en) 2004-06-17
JP2017061575A (ja) 2017-03-30
CN1246113A (zh) 2000-03-01
JP2011006472A (ja) 2011-01-13
KR20000070735A (ko) 2000-11-25
AU6263298A (en) 1998-08-25
IL130715A0 (en) 2000-06-01
EP0975609B1 (en) 2010-10-27
SK105599A3 (en) 2000-05-16

Similar Documents

Publication Publication Date Title
NO993779L (no) Fremgangsmaate for krystallisering av en revers transkriptaseinhibitor ved anvendelse av et anti-lösningsmiddel
US7860063B2 (en) Systems and methods for wireless access terminal command processing
ATE233659T1 (de) Selbstreflektierender film mit verbesserter deckschicht
GT199900100A (es) Metodo y aparato para recolectar datos de tiempo de paralizacion y equipo de fabricacion.
NO20010231L (no) FremgangsmÕte til kjemisk rensing og løsningsmiddel
DK0689579T3 (da) Fremgangsmåde til ekstraktion af sphingomyelin
EP1428818A3 (en) Method for producing N-carbamate-protected beta-aminoepoxide and beta-aminoalcohol
EA199900552A1 (ru) Асимметрический способ получения бензоксазинонов
CA2319788A1 (en) A method of modifying a crystalline molecular sieve material
AR048279A1 (es) La forma ii cristalina de cabergolina
WO2003016330A3 (en) Molecular linkers suitable for crystallization and structural analysis of molecules of interest, method of using same, and methods of purifying g protein-coupled receptors
DK1124812T3 (da) Fremgangsmåde til epoxidering af olefiner
DE60024821D1 (de) Verfahren zur reinigung von aldehydverunreinigungen
BR0204562A (pt) Método de controle para transmissão automática de veìculos motorizados
AR007400A1 (es) Metodo y dispositivo para separar una sustancia de una mezcla de liquidos mediante cristalizacion fraccional.
BR9801419A (pt) Aparelho e método para encaminhamento de instruções de armazenamento com maior probabilidade de encaminhamento
DE69901792D1 (de) Verfahren zur herstellung von 2-acetylthio-3-phenyl-propionsäure und deren salzen
DK1476422T3 (da) Fremgangsmåde til behandling af en organisk imidoplösning, som er bærer af en sulfonylgruppe
DK518587D0 (da) Fremgangsmaade til at foelge syntesen af en lineaer kombination af aminosyrerester
BR9813595A (pt) Cristal misto, processo para produzir o mesmo, e, adoçante
JPS59123944A (ja) プログラム間同期方式
Ferrara Simultaneous thermal analysis(STA)
JP3573769B2 (ja) 有線放送システム
JPS6139103A (ja) プログラマブルコントローラ
JP2004103026A (ja) 同期動作制御ｉｃ

Legal Events

Date Code Title Description
MK1K Patent expired